Table 4. Comparison of clinical features between patients with CSF IL-17⁺ and IL-17⁻ neurosyphilis.

	IL-17 negative	IL-17 positive
No. of Cases	45	58
Male No. (%)	32(71.1)	45(77.6)
Age (range), y	52(25–72)	49(26–75)
a Duration (range), mo	10(0.1–72)	12(0.1–60)
Baseline Serum RPR titer (range)	64 (1–256)	64(8–512)
CSF-WBC, cells/µl (range)	5.25(0–31.9)	5.6(0–145.2)
CSF protein, mg/dl(range)	40(14–110)	51(17–186)*
CSF VDRL titer (range)	4(0–32)	8(0–128)**
Symptomatic neurosyphilis	48.9(22/45)	70.7(41/58)*

Data are given as median (range), or frequencies.

*significant differences between the two groups,*p<0.01.

**significant differences between the two groups, **p<0.001.

^a“Duration of asymptomatic neurosyphilis” means the period between the patient's high risk behaviors which may be infected with T. pallidum and the confirmed neurosyphilis. “Duration of symptomatic neurosyphilis” means the duration of clinical manifestations.